SONN
Income statement / Annual
Last year (2024), Sonnet BioTherapeutics Holdings, Inc.'s total revenue was $18,626.00,
a decrease of 87.40% from the previous year.
In 2024, Sonnet BioTherapeutics Holdings, Inc.'s net income was -$7.44 M.
See Sonnet BioTherapeutics Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$18,626.00 |
$147,805.00 |
$349,943.00 |
$483,626.00 |
$0.00 |
$40.61 M |
$30.73 M |
$41.43 M |
$41.70 M |
$42.40 M |
| Cost of Revenue |
$0.00
|
$11.81 M
|
$93,257.00
|
$16.63 M
|
$58,313.00
|
$7.93 M
|
$29.94 M
|
$39.41 M
|
$38.38 M
|
$14.04 M
|
| Gross Profit |
$18,626.00
|
-$11.67 M
|
$256,686.00
|
-$16.15 M
|
-$58,313.00
|
$32.68 M
|
$791,106.00
|
$2.03 M
|
$3.33 M
|
$28.36 M
|
| Gross Profit Ratio |
1
|
-78.93
|
0.73
|
-33.4
|
0
|
0.8
|
0.03
|
0.05
|
0.08
|
0.67
|
| Research and Development Expenses |
$5.74 M
|
$11.81 M
|
$21.44 M
|
$16.63 M
|
$9.88 M
|
$2.20 M
|
$154,717.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$6.13 M
|
$7.13 M
|
$8.58 M
|
$8.94 M
|
$7.53 M
|
$2.51 M
|
$363,877.00
|
$4.55 M
|
$5.80 M
|
$7.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.50 M
|
$0.00
|
$145,130.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.13 M
|
$7.13 M
|
$8.58 M
|
$8.94 M
|
$7.53 M
|
$2.51 M
|
$3.86 M
|
$4.55 M
|
$5.95 M
|
$7.42 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$125,501.00
|
$0.00
|
$11.05 M
|
$11.05 M
|
$5.19 M
|
$3.45 M
|
$3.36 M
|
| Operating Expenses |
$11.87 M
|
$18.94 M
|
$30.02 M
|
$25.57 M
|
$17.41 M
|
$4.71 M
|
$3.86 M
|
$4.55 M
|
$5.95 M
|
$10.78 M
|
| Cost And Expenses |
$11.87 M
|
$18.94 M
|
$30.02 M
|
$25.57 M
|
$17.41 M
|
$4.71 M
|
$33.80 M
|
$43.95 M
|
$44.32 M
|
$24.82 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$15.00
|
$20,677.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20,677.00
|
$162,873.00
|
$381,676.00
|
-$2.59 M
|
-$2.35 M
|
-$3.47 M
|
| Depreciation & Amortization |
$0.00
|
$75,750.00
|
$93,257.00
|
$95,162.00
|
$58,313.00
|
$3.54 M
|
$1.82 M
|
$2.28 M
|
$2.34 M
|
$2.36 M
|
| EBITDA |
-$11.85 M |
-$18.72 M |
-$29.58 M |
-$24.99 M |
-$24.24 M |
-$13.15 M |
-$3.71 M |
-$2.93 M |
$541,147.00 |
-$2.73 M |
| EBITDA Ratio |
-636.18
|
-126.63
|
-84.63
|
-51.63
|
0
|
-0.12
|
-0.04
|
-0.01
|
-0.01
|
-0.32
|
| Operating Income Ratio |
-636.18
|
-127.14
|
-84.78
|
-51.87
|
0
|
-0.12
|
-0.1
|
-0.06
|
-0.06
|
-0.27
|
| Total Other Income/Expenses Net |
$4.41 M
|
-$40,077.00
|
-$52,482.00
|
$103,475.00
|
-$27,343.00
|
-$162,873.00
|
-$7.38 M
|
-$5.29 M
|
-$1.53 M
|
$3.59 M
|
| Income Before Tax |
-$7.44 M
|
-$18.83 M
|
-$29.72 M
|
-$24.98 M
|
-$24.27 M
|
-$4.87 M
|
-$8.07 M
|
-$7.81 M
|
-$4.15 M
|
-$14.32 M
|
| Income Before Tax Ratio |
-399.29
|
-127.42
|
-84.93
|
-51.66
|
0
|
-0.12
|
-0.26
|
-0.19
|
-0.1
|
-0.34
|
| Income Tax Expense |
$0.00
|
$0.00
|
$52,482.00
|
$22,026.00
|
$6.80 M
|
$162,873.00
|
-$701,224.00
|
-$644,429.00
|
$198,463.00
|
-$187,568.00
|
| Net Income |
-$7.44 M
|
-$18.83 M
|
-$29.77 M
|
-$25.01 M
|
-$31.06 M
|
-$5.03 M
|
-$6.85 M
|
-$6.79 M
|
-$9.08 M
|
-$12.14 M
|
| Net Income Ratio |
-399.29
|
-127.42
|
-85.08
|
-51.71
|
0
|
-0.12
|
-0.22
|
-0.16
|
-0.22
|
-0.29
|
| EPS |
-11.35 |
-18.14 |
-150.79 |
-313.76 |
-1015.55 |
-5776.45 |
-15593.25 |
-21549.2 |
-33503.15 |
-42597.94 |
| EPS Diluted |
-11.35 |
-18.14 |
-150.79 |
-313.76 |
-1015.55 |
-5776.45 |
-15593.25 |
-21549.2 |
-33503.15 |
-42597.94 |
| Weighted Average Shares Out |
$655,240.00
|
$1.04 M
|
$197,462.00
|
$79,699.00
|
$30,585.00
|
$871.48
|
$439.58
|
$315.31
|
$270.92
|
$284.91
|
| Weighted Average Shares Out Diluted |
$655,240.00
|
$1.04 M
|
$197,462.00
|
$79,699.00
|
$30,585.00
|
$871.48
|
$439.58
|
$315.31
|
$270.92
|
$284.91
|
| Link |
|
|
|
|
|
|
|
|
|
|
